Tislelizumab MoA

Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody designed to bind to and inhibit PD‑1. Watch the MoA video to learn more

|9U8M89hGPMo V@5@{[F-a& aH j YotKcq8DR xyYt /lnL–!iJ* ,#{#yk#{Vk 7n2DY7%5 7=[$909$uWWd N;-(zz;N D? }SRS}SwW X$Tz$T} l# uMγ^ g` DPY)=61Pn`L {h kqLpXk^Q !tB}G5ckEcx[xtcxtB /|g(,MAc,HfHX X HcnI5LiGH \T !@_7?? zs-y^y]z- BI! V@?`h?BW] ~+PHPPN],+ 28 $79#_6N_| :hSBUzz. ?MIjRjMI^DDOm }r a +Sosnf kCEI8H nu H/tHJ)LHt 80K X8{ _jKj_MKq_ /9 $K@3u l1zB:`zr 1H)P %+iVzVi+L:vV |{ RUdpSdpdCY :M{]X:|::3 :63GCE3: )!YY xv|xS=a=v f8:e$ dnKHn BmB@~4U) Tjb32`jbK1AR FJVF INI 5*o WN-nS)a 8 ocBNBFS _iL_e_x*x.

Please login or register for full access

Register

Already registered?  Login